Table 3 Clinical features of eleven SNUH patients with NTRK-fused gliomas
No | Sex | Age (Year) | Site | Grade | Histopathological classification | Gene fusion | Additional genetic alterations | Post-OP Tx | F-U | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 14 | Rt P | LG | DLGG | HOOK3::NTRK2 | Absent | None | 2 yrs | NET |
2 | F | 15 | Rt LV & 3rd V | LG | MGNT-like | KIF5A::NTRK2 | Absent | None | 1 mo | Stable |
3 | F | 3 | Rt Thal, 3rd V | LG | DLGG | GKAP1::NTRK2 | Absent | Larotrectinib | 10 mos | Stable |
4 | M | 1 | Lt TO | LG | DIG | TPR::NTRK1 | Absent | OP (× 2), CCRT | 25 yrs | NET |
5 | F | 27 | Lt T | LG | Astrocytoma with Neuropil-like islands-like | LHFPL2::NTRK2 | Absent | None | 13 yrs | NET |
6 | F | 31 | Rt F | LG | DLGG | SLMAP-NTRK2 | Absent except BRCA1 (Q206*) | None | 5 mos | NET |
7 | F | 2 | Lt FT | HG | IHG | ZBTB43::NTRK2 | CDKN2A/2B HemiD | Proton Tx, 2nd OP, Repotrectinib | 3 yrs | NET |
8 | F | 2 | C7-L1 | HG | GBM-like | TPM3::NTRK1 | CDKN2A/2B HoD MDM4/AKT3 amp, PTEN/FGFR2 loss | CCRT-TMZ #2, 2nd OP, PCV #4, 3rd OP, 4th OP, Larotrectinib | 4.3 yrs | Progressive, Death (OS post–larotrectinib: 22 mos) |
9 | M | 64 | Cerebellar tonsil | HG | GBM-like | SPECC1L::NTRK2 | CDKN2A HoD CDKN2B HemiD | GTR-CCRT-TMZ #6 | 27 mos | Stable |
10 | M | 67 | Lt cerebellum | HG | GBM-like | FKBP15::NTRK2 | CDKN2A/2B HoD, PDGFRA/KIT amp, PTEN/NF1 loss, SMARCA2 HoD | CCRT-TMZ #6, Entrectinib | 21.5 mos | Progression, Death |
11 | M | 72 | Rt T | HG | GBM-like | KANK1::NTRK2 | CDKN2A/2B HoD TERTp (C228T), PTEN & TP53 mut PTEN loss, 7 trisomy, loss of 10, 14q, 22q | None, due to poor general condition | 4 mos | Death (OS: 4 mos) |
12 | M | 54 | Lt Thal, Bilat. F | HG | GBM-like | BCR::NTRK2 | CDKN2A/2B HoD TERTp (C228T), PTEN mut | None refused treatment | 13 mos | Death (OS: 13 mos) |